Therapeutic renaissance of thalidomide in the treatment of haematological malignancies (Q36171864)

12 August 2017

1 reference

title

Therapeutic renaissance of thalidomide in the treatment of haematological malignancies (English)

1 reference

12 August 2017

0 references

Ribatti D

1

1 reference

PubMed ID

15973447

12 August 2017

Vacca A

series ordinal

2

1 reference

12 August 2017

1 September 2005

1 reference

12 August 2017

1 reference

12 August 2017

19

1 reference

12 August 2017

9

1 reference

12 August 2017

1525-1531

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403852

12 August 2017

0 references

cites work

Clinical pharmacology of thalidomide.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

THALIDOMIDE AND CONGENITAL ABNORMALITIES

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

A short history of thalidomide embryopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

A personal perspective on the thalidomide tragedy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide in dermatology. New indications for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN THE TREATMENT OF ADVANCED CANCER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide in patients with cachexia due to terminal cancer: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

The role of the vascular phase in solid tumor growth: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Angiogenesis and anti-angiogenesis in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide for previously untreated indolent or smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Current therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide: emerging role in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Treatment of Waldenstrom's macroglobulinemia with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Waldenström's macroglobulinaemia: current therapy and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide for the treatment of patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Clinical update: novel targets in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

Activity of thalidomide in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Thalidomide and its impact in dermatology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Thalidomide treatment for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Phase II evaluation of thalidomide in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Pharmacokinetics of thalidomide in an elderly prostate cancer population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403852

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403852

1 reference

12 August 2017

1 reference

PubMed ID

15973447